🇺🇸 FDA

Company profile · Sponsor

IO

IO Biotech

IOBTQ · NYSE biotech COPENHAGEN, G7, USA
Pipeline
16
Drugs
0
Patents
8

Quick answer

IO (IOBTQ) is a biotech company. headquartered in COPENHAGEN, G7, USA. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker IOBTQ
Exchange NYSE
Company type biotech
Headquarters COPENHAGEN, G7, USA
SEC CIK 0001865494

Pipeline (16)

Search pipeline →

  1. IO102-IO103

    IO

    Metastatic Melanoma

    phase 3 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, IO102-IO103

    IO

    Previously untreated, unresectable, or metastatic melanoma

    phase 3 small molecule active

    1 trial

  3. IO102

    IO

    NSCLC

    phase 2 mab completed

    1 trial

  4. IO102-IO103 in combination with pembrolizumab

    IO

    Lung Cancer Non Small Cell

    phase 2 small molecule completed

    1 trial

  5. IO102-IO103, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    IO

    Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Urothelial Bladder Cancer (mUBC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  6. IO102/IO103

    IO

    Melanoma

    phase 2 small molecule active

    2 trials

  7. IRX4204

    IO

    Psoriasis

    phase 2 small molecule on hold

    1 trial

  8. NRX 194204

    IO

    Castration Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  9. PD-L1 peptide

    IO

    Smoldering Multiple Myeloma

    phase 2 mab terminated

    1 trial

  10. PD-L1, PD-L2 peptides with Montanide ISA51

    IO

    Chronic Lymphocytic Leukemia

    phase 2 other completed

    1 trial

  11. Pembrolizumab

    IO

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  12. A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer

    IO

    advanced/metastatic solid tumors

    phase 1 other active

    1 trial

  13. IRX4204

    IO

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  14. IRX4204

    IO

    Lung Cancer, Nonsmall Cell

    phase 1 small molecule terminated

    1 trial

  15. IRX5183

    IO

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule terminated

    1 trial

  16. PD-L1/IDO Peptide Vaccine

    IO

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

Patents (8)

Search patents →

  1. US 12234288

    Immunogenic arginase 2 polypeptides

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12233103

    Indoleamine 2,3-dioxygenase based immunotherapy

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12215135

    PDL2 compounds

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12194081

    ARGINASE1 polypeptides

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12187782

    PDL1 peptides for use in cancer vaccines

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12077785

    Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11981944

    Immunogenic arginase peptides

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11878053

    Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is IO?

IO (IOBTQ) is a biotech company. headquartered in COPENHAGEN, G7, USA. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does IO sponsor?

We track 16 ClinicalTrials.gov-linked programs for IO, including IO102-IO103 and 15 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does IO company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.